Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma

References

• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–1006.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117–122.
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987;5(3):407–412.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Mundt AJ, Williams SF, Hallahan D. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin’s lymphoma: pattern of failure and implications for involved-field radiotherapy. Int J Radiat Oncol. 1997;39(3):617–625.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Moskowitz CH, Zhang Z, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009;43(12):941–948.
   PubMed Web of Science ®Google Scholar
• Coutu BG, Wilke CT, Yuan J, et al. Consolidative radiotherapy after autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(1):65–73.
   PubMed Web of Science ®Google Scholar
• Vose JM, Zhang M-J, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol. 2001;19(2):406–413.
   PubMed Web of Science ®Google Scholar
• Biswas T, Dhakal S, Chen R, et al. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol. 2010;77(1):79–85.
   PubMed Web of Science ®Google Scholar
• Kahn ST, Flowers CR, Lechowicz MJ, et al. Refractory or relapsed Hodgkin’s disease and non-Hodgkin’s lymphoma: optimizing involved-field radiotherapy in transplant patients. Cancer J Sudbury Mass. 2005;11(5):425–431.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero MD, Gutierrez A, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol. 2004;15(10):1504–1509.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Lifton R, Constine LS, et al. Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1997;19(9):883–890.
   PubMed Web of Science ®Google Scholar
• Aref A, Narayan S, Tekyi-Mensah S, et al. Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin’s lymphoma. Radiat Oncol Investig. 1999;7(3):186–191.
   PubMedGoogle Scholar
• Tseng YD, Chen Y-H, Catalano PJ, et al. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Int J Radiat Oncol. 2015;91(1):223–231.
   PubMed Web of Science ®Google Scholar
• Withers HR. Biologic basis for altered fractionation schemes. Cancer. 1985;55(S9):2086–2095.
   PubMedGoogle Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346.
   PubMed Web of Science ®Google Scholar
• Ng AK, Yahalom J, Goda JS, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol. 2018;100(3):652–669.
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.
   PubMed Web of Science ®Google Scholar
• Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol. 1999;52(2):137–148.
   PubMed Web of Science ®Google Scholar
• Norin T, Onyango J. Radiotherapy in Burkitt’s lymphoma conventional or superfractionated regime—early results. Int J Radiat Oncol. 1977;2(5–6):399–406.
   PubMed Web of Science ®Google Scholar
• Martens C, Hodgson DC, Wells WA, et al. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin’s lymphoma. Int J Radiat Oncol. 2006;64(4):1183–1187.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Moskowitz CH, Filippa DA, et al. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. J Clin Oncol. 2008;26(11):1858–1864.
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316(24):1493–1498.
   PubMed Web of Science ®Google Scholar
• Petersen FB, Appelbaum FR, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol. 1990;8(4):638–647.
   PubMed Web of Science ®Google Scholar